anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Angioedema: Angioedema has been reported in patients receiving lisinopril and hydrochlorothiazide, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face; extremities, lips, tongue, glottis and/or larynx occurs, treatment with lisinopril and hydrochlorothiazide should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.) In rare cases, intestinal angioedema has been reported with angiotension converting enzyme inhibitors including lisinopril. (see WARNINGS.)

Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: hypotension (1.4), orthostatic hypotension (0.5), other orthostatic effects (3.2). In addition syncope occurred in 0.8 percent of patients. (See WARNINGS.)
Selenium was recognized as a non-toxic element in the second half of the 20th century. Since then, the positive impact of selenium on the functioning of the human body has been noticed. It has been shown that low levels of selenium in the body are significantly associated with a higher risk of developing cancer. Selenium acts as an antioxidant and inhibits the proliferation of cancer cells. It has been shown that selenium supplementation may contribute to reducing the risk of DNA mutations and carcinogenesis. Nanomedicine has become very helpful in both the diagnosis and treatment of cancer. Due to its anticancer properties, selenium is used in nanotechnology as selenium nanoparticles.
PURPOSE: Provided is a composition comprising an extract of Zizania latifolia TURCZ. having HCV inhibiting activity. Therefore, it is useful for medicine and health food supplements for the prevention and treatment of HCV. CONSTITUTION: A composition is characterized by comprising an extract of Zizania latifolia TURCZ. having prevention and treatment effects on HCV. The extract is obtained by using a polar solvent, such as water and butanol or nonpolar solvent, such as ethylacetate and chloroform solvent. The composition contains 0.5-50% of the extract, based on the total weight of the composition.
The invention relates to summer-heat-clearing tea, which is characterized by being prepared from the following raw materials: 5-16 g of fresh agastache rugosus, 3-10 g of fresh herba eupatorii, 5-12 g of fresh lotus leaf, 5-10 g of fresh bamboo leaf, 3-10 g of fresh mint, 4-10 g of fresh reed rhizome and 3-10 g of fresh dendrobium. A processing method of the above summer-heat-clearing tea comprises the following steps: chopping the above seven raw materials, adding water and decocting, removing slag and fetching a decoction. The product is drunk as tea twice or three times for each day. The summer-heat-clearing tea has a scientific and reasonable formula, has remarkable treatment effects, has effects of clearing away heat and toxic materials and promoting the production of body fluid to quench thirst, and is obvious in mainly treating infantile summer fever and thirst. The treatment mode is easy to accept by children. The summer-heat-clearing tea has a good application prospect.
The invention relates to a preparation method of a xylitol liver-protecting tablet, belonging to the technical field of medical health care. The formula of the xylitol liver-protecting tablet comprises the following raw materials in proportion: 15-45 parts of kudzu root extract, 2-20 parts of glycyrrhizic acid, 5-35 parts of propolis powder, 20-60 parts of xylitol, 1-10 parts of low-substituted hydroxypropyl cellulose, 1-10 parts of cross-linked sodium carboxymethyl cellulose and 0.5-5 parts of magnesium stearate; and a coating agent comprises 0.5-40 parts of hydroxypropyl methylcellulose, 1-30 parts of polyethylene glycol 6000, 0.5-40 parts of talcum powder, 0.5-30 parts of titanium pigment, 0.5-30 parts of iron oxide brown and 10-75 parts of maltitol. The finished product of the xylitolliver-protecting tablet is prepared by the processing steps of crushing, mixing, tabletting, coating and the like. In the invention, by using the xylitol as a main raw material and adding partial auxiliary materials, the xylitol liver-protecting tablet which is a health food and has auxiliary protection effect on chemical liver injury is prepared. The xylitol liver-protecting tablet can effectively prevent and treat fatty liver; and after patients suffering from the fatty liver take the xylitol liver-protecting tablet, severe fatty liver can be relieved into moderate fatty liver, and moderate fatty liver can be relieved into mild fatty liver. Thus, the xylitol liver-protecting tablet has obvious benefit to improve liver functions of human bodies and has wide market prospects.
Impaired Liver Function   
Do not use Junel Fe 24 in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Junel Fe 24 if jaundice develops.

Liver Tumors   
Junel Fe 24 is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
Hemolysis is the most prevalent pre-analytical interfering factor and a major source of error in laboratory analysis. The examination of samples post-centrifugation can provide valuable information regarding pre-analytical interferences. In this unusual case, a patient's plasma specimen was cherry-red after centrifugation, which is most usually indicative of hemolysis. However, subsequent investigations ruled out common hemolysis causes. We eventually determined that the patient's cherry-red plasma was most likely caused by other factors in the patient's medical history, including cancer treatment with PV-10 (rose bengal disodium 10%). We then conducted an interference study to comprehensively assess the effects of PV-10 on various biochemical tests, especially liver function tests and bilirubin levels. The findings indicate that PV-10 has varying effects on different biochemical assays and test results should be examined individually. This report underlines the need for awareness of potential drug interference on laboratory tests for better result interpretation and making clinical decisions.
The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
OBJECTIVE: To investigate the efficacy and safety of tirofiban and low molecular weight heparin (LMWH) in the treatment of patients undergoing acute progressive pontine infarction.
PATIENTS AND METHODS: Patients with acute progressive pontine infarction who were hospitalized in the Neurology Department from June 2021 to June 2023 were included in the study and randomly divided into two groups, namely the experimental group (tirofiban group) and the control group (LMWH group). All patients in both groups were required to receive conventional comprehensive treatment and dual antiplatelet therapy with aspirin + clopidogrel at the beginning of admission. The National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) were used to evaluate the neurological deficits on the first day of admission, the next day with stroke progression, and at discharge after treatment with tirofiban and LMWH, respectively in the two groups. The modified Rankin Scale was employed to assess prognosis on the 90th day after treatment. Clinical adverse events were followed up for 90 days, comparing the clinical efficacy and safety of the two treatment methods.
RESULTS: There was no statistical significance in NIHSS score and Barthel Index between the tirofiban group and the LMWH group on the first day of admission and the next day with stroke progression (p > 0.05). After stroke progression, tirofiban and LMWH were separately used for treatment in the two groups. We found that the NIHSS score of the tirofiban group was lower than that of the LMWH group, and the Barthel Index score was higher than that of the LMWH group at discharge (p < 0.05). After three months of follow-up, the mRS score of the tirofiban group was dramatically higher than that of the LMWH group (p < 0.05). No significant harmful or adverse reactions, such as bleeding events, were found in the two groups (p > 0.05).
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by autoantibody production and organ involvement. The role of toll-like receptor-7 in SLE is well established. Although genetic variations in the TLR-7 gene have been associated with an increased risk of developing SLE, the findings are not consistent. We performed a meta-analysis of previously published articles on four important single nucleotide polymorphisms in the TLR-7 gene (rs3853839, rs179008, rs179019, and rs179010) to reach a valid conclusion. Various literature databases, including PubMed, Science Direct, and Scopus, were scoured for eligible reports until May 10, 2023. GPower software v.3 was used to assess the power of individual reports included in the meta-analysis. Comprehensive Meta-analysis v3 software was used to perform all statistics. The publication biases in each genetic comparison model were investigated using funnel plots and Egger's regression test. To test heterogeneity, Cochrane Q statistics, probability value and I2 were used. Considering the predefined inclusion and exclusion criteria, the current study included a total of 10 eligible studies that included 15,472 SLE cases and 16,721 healthy controls. The meta-analysis revealed a significant association between TLR7 polymorphisms (rs179019 and rs179010) and susceptibility to SLE development. Other TLR7 polymorphisms (rs3853839 and rs179008), on the other hand, showed no significant association. Furthermore, the trial sequential analysis identified the need for additional case control studies for TLR-7 polymorphisms (rs3853839, rs179008, and rs179019) other than the rs179010 polymorphism. TLR7 variants for rs179010 and rs179019 are risk factor for the development of SLE. Further investigations are required to reach a valid conclusion.
Klatskin tumours are a form of bile duct cancer. They are generally not diagnosed until quite late and a curative operation is rarely a possibility. Their anatomic location usually results in bile duct obstruction and the aim of therapy is thus to keep the ducts open. This is accomplished through endoscopic retrograde cholangiopancreatography (ERCP) by implanting stents. Stent therapy combined with photodynamic therapy (PDT) extends life expectancy. PDT requires an injection of photosensitizer that is absorbed primarily by the cancer cells. Light of a particular wavelength is then applied with ERCP to kill the cancer cells. Drawbacks include not only high costs and poor availability, but foremost that patients have to avoid direct sunlight for a period of weeks. Radio frequency ablation (RFA) together with stent implantation constitutes an alternative by which the cancer cells are killed through heat applied during ERCP. The RFA technology is more widely available and easier to deploy. However, it has not been studied extensively and no randomized trials exist comparing the two methods. This trial will compare survival in patients with Klatskin tumours depending on whether they receive PDT or RFA. Moreover, data will be collected on side-effects and quality of life.
A non-biodegradable endodontic sealant composition comprises the reaction product of a first paste and a second paste. Either paste or both pastes include one or more of: unmodified HEMA and bioglass. The first paste includes a first polymerizing agent and the second paste includes a second polymerizing agent. A method for making the composition comprises preparing the first paste and second paste and combining the pastes under conditions to achieve a polymerization reaction initiated by a reaction between the polymerizing agents. The combining step is performed under conditions for achieving a setting time that is in a range of about 1 minute to about 1 hour. A method for treating humans having a voided region into which no re-growth will occur comprises administering the composition to the affected area, preferably to an area where tissue, tooth, or bone are not intended to re-grow.
An apparatus for real-time control of glucose in a human or animal is provided. A sensor provides a time series of measurements of glucose level that indicate an inferred level of the glucose. A processor calculates a first estimate of the inferred glucose level from the measured glucose level using a first glucoregulatory system model, calculates a second estimate using a second glucoregulatory system model, and predicts a combined estimate. The processor is a state estimator defining a state vector that has variables with an associated uncertainty. The state vector includes various states, based on glucose amounts in the accessible, non-accessible, and interstitial compartments excluding the contribution from meals, the unexplained glucose influx, and glucose availability. A dispenser delivers a specified amount of medication to a user in response to a command from the processor based on the predicted combined estimate of the inferred glucose level.
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity, capable of preventing coloring of toothbrush hair due to a natural pigment compound, improved in aesthetic property and having high commercial value by compounding polyvinylpyrrolidone into a composition containing a natural pigment compound. SOLUTION: Polyvinylpyrrolidone is compounded, preferably in an amount of 0.01-1 wt.% in a composition containing a natural pigment compound (e.g. caramel), preferably in an amount of 0.0001-0.01 wt.% based on whole composition to provide the objective composition. A material having 40,000-50,000 weight average molecular weight and 5,000-20,000 number-average molecular weight is preferable as polyvinylpyrrolidone. The composition can be prepared in dentifrices such as tooth paste, wet dentifrice or liquid dentifrice and mouthwash agent, etc. An abrasive (e.g. sedimentary silica), a viscolizer (e.g. glycerol), a binder (e.g. carboxymethyl cellulose sodium), a surface-active agent (e.g. sodium lauryl sulfate), etc., can be compounded into the composition.
<P>PROBLEM TO BE SOLVED: To impart discriminability from other liquid agents in operation processes, and to avoid the occurrence of an immediately injectable form.  <P>SOLUTION: This topical styptic medicine composition sealed in a flexible container to administer the composition on an endoscopic treatment or the like. The flexible container is composed of a flexible container body 1, a nozzle-having cap 2 mounted on the mouth portion 101 of the main body, and a nozzle cap 3. The bellows portion 105 of the container body 1 is pressed and compressed with fingers to jet the medicine liquid in the container into a washing tube or the like. Consequently, a medical treatment error based on an injection misuse liable to be caused on the administration of a conventional topical styptic medicine composition can be prevented.  <P>COPYRIGHT: (C)2004,JPO
In the intermittent phototherapy group, phototherapy will be applied for 1 hour, phototherapy will be turned off for 2 hours, and time will be left for cleansing from the skin. The 3-hour cycle is completed twice and the 6-hour session is completed, and at the end, the total bilirubin will be measured and the hourly bilirubin decrease rate will be calculated.
Participants assigned to this group will not have access to the W-PPMA mobile app during the treatment phase (first 8 weeks) of the study. They will have access during the follow-up phase (last 8 weeks) of the study and will be instructed to use the app for at least 5 minutes a day.
PURPOSE:To measure human chorionic gonadotropin (hCG) accurately with high sensitivity by a sandwich method by producing the antibody reacting specifically with the hCG out of the antibodies held on a carrier and marked antibodies by a specific method and using the same. CONSTITUTION:Reptide consisting of about 30 members of amino acids at the C terminal of the hCG-beta expressed by the formula is synthesized by a conventional method. The antibody which is obtd. by inoculating said peptide and protein for a carrir (bovine thyroglobulin, etc.), which are condensated in the presence of glutaraldehyde, in a warm-blooded animal (a rabbit or the like) and reacts specifically with the hCG is obtained. Such antibody is deposited on polyestyrene particles. On the other hand, the antibody consisting of marking the antibody obtd. by immunizing the hCG obtd. from human urine in an eel with beta-D-galactosidase, etc. is obtd. The deposited antibody, the marked antibody, and the hCG in the specimen (bodily fluid such as serum) are caused to react, and the activity of the mark bound with the carrier or the activity of the mark in the unreacted marked antibody is measured. It is measured accurately without disturbance of other protein and the like causing cross reaction with the hCG, and the diagnosis of pregnancy and the like are accomplished accurately.
Subjects will apply VYN201 1.0% once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to 1.0% will remain and continue on the same dose until Week 52.
Postdilution on-line hemodiafiltration (OL-HDF) is considered the most efficient renal replacement treatment modality. Compared with conventional hemodialysis (HD), OL-HDF enables a better removal of middle molecular weight uremic toxins by combining convective and diffusive clearance. Although higher convection volume exchange has been associated with an increased survival advantage for dialysis patients, the mechanisms by which OL-HDF may improve outcomes remain unknown.

On the basis of improved toxin removal, a potential benefit of OL-HDF on nutritional status has been postulated. However, evidence on the effect of OL-HDF on nutritional status is scarce and at times conflicting. Some observational and interventional studies have suggested that OL-HDF is associated with improved nutritional parameters; others have found no effect; and one study even reported negative effects of OL-HDF on nutritional status. The majority of these observations come from cohort studies, non-controlled interventions and/or secondary analysis of controlled trials. Further, there are currently no data examining the plausible effect of postdilution OL-HDF on body composition. To clarify this important knowledge gap, this prospective, controlled, study evaluated the effects of high volume postdilution OL-HDF on nutritional status and body composition in prevalent HD patients.
The present invention discloses a novel ethoxy combretastatin (Combretastatin) and the whole synthesis process of the former drug. The 4' location of the combretastatin B aromatic ring is chemically modified by ethoxy. At the same time, the 3' location hydroxide of the combretastatin B aromatic ring is changed into phosphate  or water-solution former drug of phosphorylcholine in-type salinity. The 3' location amido combretastatin experiences chemical modification of the 4' location ethoxy. Fatherly, amino acid side chain is introduced to the amido to get amino acid amide water-solution former drug. The structure is shown in (1). ethoxy combretastatin is of strong inhibition in the concentration of canaliculus albumen, and can be used in the anti-tumor treatment and anti-angiogenesis therapy.
Hypoxia, low, non-physiological oxygen tension is a key regulator of tumor microenvironment, determining the pathological tumor vascularization. Alleviation of hypoxia through vessel normalization may be a promising therapeutic approach. We aimed to assess the role of low oxygen tension in PTEN-related pathways and proangiogenic response, in vitro, in two different tumor cell lines, focusing on potential therapeutic targets for tumor vessel normalization. Downregulation of PTEN in hypoxia mediates the activation of distinct mechanisms: cytoplasmic pAKT activation in melanoma and pMDM2 modulation in kidney cancer. We show that hypoxia-induced proangiogenic potential was stronger in Renca cells than B16 F10-confirmed by a distinct secretory potential and different ability to affect endothelial cells functions. Therefore, the impact of hypoxia on PTEN-mediated regulation may determine the therapeutic targets and effectiveness of vessel normalization and intrinsic characteristics of cancer cell have to be taken into account when designing treatment.
Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
PURPOSE: To provide a medicine contg. 1,2-dithiol-3-thion-S-oxide compd. contg. a new compd. as an active ingredient and exhibiting excellent hepar protecting characteristics and excellent compatibility and being useful for prevention and curing of hepatopathy caused by chem. toxicant.  
     CONSTITUTION: 1,2-Dithiol-3-thion-S-oxide compd. of pharmacologically effective amt. of formula I (wherein R 1  is H, a 1-2C alkyl, a lower alkoxy, OH, a halogen, CF 3  or NO 2 ; R 2  is H, a halogen or a lower alkoxy or R 1  and R 2  together form a 1-2C alkylene dioxy), e.g. a new substance 1,2-dithiol-3-thion-S-oxide compd. of formula II (R 1 ' is a group excluding H from R 1 ) and a pharmacological auxiliary and/or a carrier in ordinary use are incorporated. The above described new compd. of formula II is obtd. by oxidizing the compd. of formula III. The medicine is effective for prevention and curing of hepatopathy, etc., caused by medicines, radiation, etc., being the toxic amt. to the hepar. 
     COPYRIGHT: (C)1990,JPO